Technology & Platform
Richard DiMarchi is one of the world’s leading peptide chemists. He has successfully designed multiple peptide-based drugs and drug candidates. His research group is well recognized for discovery of novel chemical approaches to drug discovery and their application to the design of peptides with optimized pharmacological characteristics.
Native peptide hormones are challenging to use as drugs. By contrast, peptides designed using our chemical technology and state-of-the-art experience have significantly enhanced pharmacokinetics and pharmacodynamics relative to native sequence. Importantly, these characteristics can be fine-tuned based upon reproducible chemical strategies that have been well proven in endocrine diseases.
In the news…
MBX Biosciences announced today the appointment of Kent Hawryluk to the position of President & CEO. Mr. Hawryluk is a Co-founder and a member of MBX’s Board of Directors. Additionally, Greg Davis has been appointed to the position of Vice President, Product Development.
MBX Biosciences Inc., founded by Indiana University Bloomington Distinguished Professor Richard DiMarchi, IUPUI alumnus Kent Hawryluk and Tim Knickerbocker, announces closing of seed funding, securing investments from the Indiana University Philanthropic Fund, Twilight Venture Partners II, and BioCrossroads.